BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Eric Stephen Winer, MD
Study ID
NCT05703542
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BXCL701 — DRUG
    Tablet, taken Orally

Study Details

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701

Key Dates

Start date
Feb 2, 2023
Status verified
Jul 2025
Primary completion
Mar 17, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation BXCL701
    Dose escalation will occur using a 3+3 dose escalation approach, evaluating 4 different dose levels of BXCL701. During each 28 day study cycle participants will take BXCL701 2x daily for up to 12 cycles.

Primary Outcome Measure

Maximum Tolerated Dose (MTD) [ Time Frame: From initiation of therapy to day 28, up to 35 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215
Eric s Winer, MD
[email protected]
617-632-3000
Eric S. Winer, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Leukemia (other)
By specialty
OncologyBlood cancer
By research site
Dana Farber Cancer Institute· Boston, MA

Related Studies